Key Points
- Venrock Healthcare Capital Par sold 174,645 KalVista shares at an average price of $16.95, totaling $2,960,232.75 and reducing its stake by 3.29% to 5,129,340 shares, as disclosed in an SEC Form 4 filing.
- KalVista shares have risen (opened $19.33, near a 52‑week high) amid several analyst target increases (e.g., Stifel $42, Needham $36, HC Wainwright $37) and a reported $49.1M in EKTERLY revenue, fueling bullish sentiment.
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par sold 39,986 shares of the company's stock in a transaction on Thursday, March 26th. The shares were sold at an average price of $18.28, for a total transaction of $730,944.08. Following the completion of the sale, the insider directly owned 5,089,354 shares in the company, valued at approximately $93,033,391.12. This represents a 0.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company's stock are required to disclose their sales and purchases with the SEC.
Venrock Healthcare Capital Par also recently made the following trade(s):
- On Wednesday, March 25th, Venrock Healthcare Capital Par sold 174,645 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $16.95, for a total transaction of $2,960,232.75.
KalVista Pharmaceuticals Price Performance
Shares of NASDAQ KALV opened at $19.33 on Friday. The company has a market capitalization of $990.08 million, a PE ratio of -4.89 and a beta of -0.35. The company has a quick ratio of 7.21, a current ratio of 7.22 and a debt-to-equity ratio of 8.18. KalVista Pharmaceuticals, Inc. has a twelve month low of $9.23 and a twelve month high of $19.95. The firm has a fifty day simple moving average of $16.04 and a 200 day simple moving average of $14.46.
Analysts Set New Price Targets
Several equities research analysts recently commented on the company. Citizens Jmp cut their target price on KalVista Pharmaceuticals from $29.00 to $28.00 and set a "market outperform" rating on the stock in a research report on Thursday. Weiss Ratings reiterated a "sell (d-)" rating on shares of KalVista Pharmaceuticals in a report on Thursday, January 22nd. Needham & Company LLC boosted their price target on KalVista Pharmaceuticals from $35.00 to $36.00 and gave the company a "buy" rating in a research note on Wednesday. TD Cowen restated a "buy" rating on shares of KalVista Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Wall Street Zen raised shares of KalVista Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday. Seven investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $32.60.
Check Out Our Latest Stock Report on KALV
Hedge Funds Weigh In On KalVista Pharmaceuticals
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Tudor Investment Corp ET AL bought a new stake in KalVista Pharmaceuticals in the 3rd quarter valued at about $24,360,000. Emerald Advisers LLC boosted its holdings in KalVista Pharmaceuticals by 30.2% in the third quarter. Emerald Advisers LLC now owns 1,351,254 shares of the specialty pharmaceutical company's stock worth $16,458,000 after acquiring an additional 313,205 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $3,494,000. Blue Owl Capital Holdings LP acquired a new stake in KalVista Pharmaceuticals in the third quarter valued at approximately $1,522,000. Finally, Stonepine Capital Management LLC increased its holdings in shares of KalVista Pharmaceuticals by 364.0% during the second quarter. Stonepine Capital Management LLC now owns 100,000 shares of the specialty pharmaceutical company's stock valued at $1,130,000 after acquiring an additional 78,450 shares in the last quarter.
Key KalVista Pharmaceuticals News
Here are the key news stories impacting KalVista Pharmaceuticals this week:
- Positive Sentiment: Unusual bullish options flow: traders bought 5,072 call options (≈569% above the average of 758), suggesting speculative or hedged bullish positioning that can amplify near-term upside interest in the shares.
- Positive Sentiment: Stifel Nicolaus raised its price target to $42 and reiterated a "buy" rating — a large upside vs. the current level that often attracts renewed investor attention and buying. Stifel price target raise
- Positive Sentiment: Needham & Company increased its target to $36 and kept a "buy" rating, reinforcing analyst conviction from multiple firms. Needham target raise
- Positive Sentiment: EKTERLY commercial launch showing strong initial revenue: KalVista reported $49.1M in EKTERLY revenue during an eight-month transition period — a material commercial proof point that supports revenue growth expectations. EKTERLY revenue report
- Positive Sentiment: Stock hit a new 52-week high after analyst upgrades and increased coverage, a technical signal that can attract momentum buyers. 52-week high / analyst upgrade
- Neutral Sentiment: Recent earnings materials (Q1 2025 call summary and transcript) have been published — useful for revisiting guidance and management commentary but the market reaction depends on details and forward guidance. Q1 2025 earnings call summary
- Negative Sentiment: Citizens Jmp trimmed its price target slightly from $29 to $28 (still a "market outperform"), a modest downtick in one analyst’s view that could temper upside expectations if other firms follow. Citizens Jmp target change
KalVista Pharmaceuticals Company Profile
(
Get Free Report)
KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm's scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista's approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.
The company's lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
